Formoterol nur IHP 6µg (R03AC13)

TENDER DESCRIPTION

The Kaufmännische Krankenkasse – KKH (hereinafter referred to as KKH) pursues the objective of concluding discount agreements pursuant to Section 130a(8) of SGB V with all suitable pharmaceutical companies for the active ingredient stated under BT-21-Lot (ATC) and, if applicable, restrictively to certain dosage forms within the framework of a so-called "Open-House procedure". Under the requirement of uniform contract terms and a uniform access procedure, the conclusion or accession to a discount agreement pursuant to Section 130a(8) of SGB V for the above-mentioned active ingredient is offered to all suitable and interested pharmaceutical companies or associations of pharmaceutical companies. Interested pharmaceutical companies may request the participation documents and the contract at the contact address stated. A prerequisite for concluding a contract is that the interested pharmaceutical company submits the requested participation documents fully completed and duly signed. A contract is concluded with each pharmaceutical company that meets the participation requirements. Exclusivity is not provided. Accession or contract conclusion may be carried out at any time and under the…

TENDER BRIEF

TENDER DOCUMENTS